Introduction {#s1}
============

Obesity is a growing social problem affecting an increasing number of women in reproductive age. It represents a risk factor potentially impairing the pregnancy itself, and even the long-term outcome of the offspring, since it is well known that the overweight condition can be transmitted to the future generations. Several observational studies and some meta-analyses have been carried out to assess whether breastfeeding is positively correlated with a reduction in the incidence of obesity in later life. Although most of them showed a modest reduction in such risk ([@B1]), rigorous reviews ([@B1]--[@B3]) conclude that there is no clear cause-effect relationship, because of several confusing factors and frequent bias of such studies. Currently, conditions as the socio-economic status of the mother, the level of education, ethnicity, eating habits of the family, and duration of breastfeeding have not been considered and could themselves justify the association. On the other hand, a study reports that the risk of obesity is higher in the non-breastfed children of obese mothers, but remains higher even in those who are breastfed than in the general population ([@B4]).

Nutrition in the early stages of life plays a fundamental role in the child\'s growth and development, and is presumably one of the main players in the "programming" of his future health. In the very early phases of life breast milk (BM) can affect the maturation of organs and systems, influencing the future health.

Human BM is a complex biofluid containing a very large number of components, including macronutrients, hormones, bioactive molecules, stem cells, and microbial communities; each of them is potentially responsible for a certain specific and even synergic influence on the newborn outcome, on its growth and on the development of organs and systems, as deeply reviewed in several paper by ours ([@B5]--[@B10]).

It could be hypothesized that maternal pathological conditions could influence BM composition, but there are few studies in agreement with these considerations. In a recently published review by our group, to our knowledge the first on this topic, the studies using metabolomics to investigate BM of women with great obstetrical syndromes were discussed; it emerged that some metabolites seem to differentiate BM of healthy women and samples collected from women with preeclampsia, gestational diabetes, and intrauterine growth restriction; these metabolites might be related to the long-term outcomes in the offspring of affected mothers. The results of the analysis seem to highlight the involvement of the mammary gland in the underlying pathological processes and suggest the possibility that BM, while remaining the food of first choice in the early stages of life, could benefit from targeted supplementation to promote a better infant outcome ([@B11]).

Up to now, a clear description of BM composition in overweight or obese mothers has not been provided. Metabolomics is an emerging method in the study of BM and has proved useful in differentiating the characteristics of healthy women milk according to gestational age and lactation stage ([@B12]--[@B14]).

In the present paper, through the review of the metabolomics studies on BM collected from overweight-obese women, for the first time, we aim to investigate the metabolites found altered in the different studies, to assess whether they can have a positive (or negative) effect on the onset of obesity and other long-term complications.

We accurately searched on Medline the whole available literature, in English language, applying metabolomics to characterize BM in overweight and obese mothers; thus, breast milk, overweight, obesity, metabolomics, lipidomics, and oligosaccharides were used as key words.

As result, we found and discussed a single article on untargeted metabolomics ([@B15]), a total of four articles on targeted metabolomics ([@B16]--[@B19]), and 10 articles on lipidomics ([@B20]--[@B29]) published since 2013--2020. Review articles were excluded.

The main metabolomics differences detected by comparing BM of overweight/obese mothers and lean ones, and the potential short- and long-term effects in offspring have been summarized in [Table 1](#T1){ref-type="table"}. When available, details on maternal age in the different studies have been reported in the footnotes.

###### 

Main metabolomics differences detected by comparing breast milk of overweight/obese mothers and lean ones in the different studies, and the potential short- and long-term effects in offspring.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Metabolites variation in overweight/obese mothers samples**                                                             **Potential long term effects in offspring**
  ------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  **PYRIMIDINE DERIVATIVES**                                                                                                

  **Orotate**\                                                                                                              Altered glucose homeostasis\
  ↓ at 1 month of lactation ([@B15])                                                                                        More weight gain by an inadequate diet\
                                                                                                                            Negative effect on the development of immune processes

  **PURINE DERIVATIVES**                                                                                                    

  **AMP, Adenine**\                                                                                                         ↑ Overweight risk\
  ↑ at 1 month of lactation ([@B15])                                                                                        Protection from obesity associates insulin-resistance\
                                                                                                                            Positive effect on the development of immune processes\
                                                                                                                            ↑ Neuroprotection\
                                                                                                                            ↓ Cardio-vascular risk

  **Methylthioadenosine**\                                                                                                  Protection against cardio-metabolic risk
  ↑ at 1 month of lactation ([@B15])                                                                                        

  **SUGAR ALCOHOLS**                                                                                                        

  **Erythritol**\                                                                                                           ↑ Overweight risk
  ↑ at 1 month of lactation ([@B15])                                                                                        

  **AMINOACIDS (AND ACYLCARNITINES)**                                                                                       

  **Branched chain aminoacids (BCAAs)**\                                                                                    ↑ Cardio-metabolic risk\
  ↑ at 3 month of lactation ([@B16])                                                                                        Unfavorable neurological outcomes

  **3-5Acylcarnitines (ACs)**\                                                                                              
  ↑ at 6 month of lactation ([@B15])                                                                                        

  **Glutamine**\                                                                                                            Altered glucose homeostasis\
  ↓ at 6 months of lactation ([@B15])                                                                                       Unfavorable neurological outcomes\
                                                                                                                            (as precursor of glutamate)

  **Asparagine** and **Ornithine**\                                                                                         ↑ Cardio-metabolic risk
  ↓ at 6 months of lactation ([@B15])                                                                                       

  **Aromatic aminoacids and derivatives**                                                                                   

  **Tyrosine**\                                                                                                             ↑ Cardio-metabolic risk
  ↑ at 6 months of lactation ([@B16])                                                                                       

  **Kynurenic acid**\                                                                                                       Protection against cardio-metabolic risk from oxidative stress and inflammation
  ↓ at 6 months of lactation ([@B15])                                                                                       

  **2-Aminobutyrate (2-AB)**\                                                                                               Protection against oxidative stress
  ↑ at 1 month of lactation ([@B15])                                                                                        

  **Polyamines**\                                                                                                           Less protection against cardio-metabolic risk from oxidative stress and inflammation\
  ↓ at 3 days, 1 month and 6 months of lactation ([@B17])                                                                   Less neuroprotection

  **MONOSACCHARIDES**                                                                                                       

  **1-5 anhydroglucitol (1,5-AG)**\                                                                                         Emerging hyperglycemia marker\
  ↑ at 1 and 6 months of lactation ([@B15])                                                                                 **In breast milk**\
                                                                                                                            Potential role in describing maternal glycemic control

  **Arabinose**\                                                                                                            Effects on some pathogens, potentially reducing their virulence
  ↑ at 6 months of lactation ([@B15])                                                                                       

  **Glucose-6-phosphate**\                                                                                                  Protection against oxidative stress\
  ↑ at 6 months of lactation ([@B15])                                                                                       Providing of energy supply

  **OLIGOSACCHARIDES**                                                                                                      

  **Lacto-N-fucopentaose I**\                                                                                               ↑ Overweight risk\
  ↓ at 1 month of lactation ([@B15])                                                                                        ↓ Infant height\
                                                                                                                            ↓ Protection against infections\
                                                                                                                            Negative influence on neonatal gut microbiota, i.e., reducing *Lactobacillus* spp. ([@B30])

  **Lacto-N-fucopentaose II**\                                                                                              ↑ Overweight risk
  ↑ at 1 month of lactation ([@B15])                                                                                        

  **Lacto-N-fucopentaose III**\                                                                                             ↑ Infant height promotion\
  ↑ at 1 month of lactation ([@B15])                                                                                        ↑ Protection against infections\
                                                                                                                            ↑ Gut content of *Lactobacillus* spp. ([@B30])

  **2′-Fucosyllactose**\                                                                                                    No clear associations with infant growth\
  ↓ at 1 month of lactation ([@B15])\                                                                                       Its reduction could lead to: ↓ Infant weight, height and growth promotion ↓ Protection against infections
  Higher in *Se+* overweight mothers than *Se+* non-overweight ones (observation not confirmed in obese mothers) ([@B18])   

  **3′-Fucosyllactose**\                                                                                                    No clear associations with infant growth
  ↑ at 1 month of lactation ([@B15])\                                                                                       
  Lower in *Se+* overweight mothers than *Se+* non-overweight ones. (observation not confirmed in obese mothers) ([@B18])   

  **Lacto-N-hexaose**\                                                                                                      ↓ Overweight risk
  ↓ at 3-4 months of lactation ([@B19])                                                                                     

  **LIPIDS**                                                                                                                

  **Saturated fatty acids**\                                                                                                ↑ Weight and BMI gain up to 13 months
  ↑ At 1 and 2 months ([@B23], [@B24]), and at 3 months of lactation ([@B21])                                               

  **Palmitic acid (16:0)**\                                                                                                 ↑ Overweight risk\
  ↑ at 2 weeks of lactation ([@B25])\                                                                                       ↓ Glucose tolerance\
  **Tridecanoic acid (C13:0)**\                                                                                             ↓ Insulin response\
  ↑ in colostrum ([@B26])                                                                                                   ↓ Oxidation of fatty acids\
                                                                                                                            ↑ Inflammatory and metabolic responses

  **MUFA/SFA, UFA/SFA**\                                                                                                    ↑ Weight and BMI gain up to 13 months
  ↓ at 3 months of lactation ([@B21])                                                                                       

  **Total MUFA**\                                                                                                           ↑ Overweight risk\
  ↓ at 1--3 months of lactation ([@B22], [@B23])\                                                                           Worsening of metabolic and lipid profiles
  **Oleic acid (18:1)**\                                                                                                    
  ↓ at 2 weeks of lactation ([@B25])                                                                                        

  **n3 PUFA**\                                                                                                              ↑ Overweight risk\
  ↓ at 1--3 months ([@B21], [@B22], [@B29]) and at 6--7 months of lactation ([@B20])\                                       ↑ Inflammation
  ↓ from 3 days to 2 months of lactation ([@B24])\                                                                          
  ↑ in colostrum ([@B26])                                                                                                   

  **ALA, EPA, DHA**\                                                                                                        ↑ Overweight risk\
  ↓ at 1--3 months of lactation ([@B22], [@B23], [@B29]) and from 3 days to 2 months of lactation ([@B24])                  Unfavorable sensorineural outcome

  **n-6 PUFA**\                                                                                                             ↑ Weight for age z-score\
  ↑ at 2 months of lactation ([@B29]) and at 6--7 months of lactation ([@B20])\                                             ↓ Lengh for age z-score and CC between 2 weeks and 2 months of age\
  **DGLA**\                                                                                                                 ↑ Inflammation
  ↑ at 2 weeks of lactation ([@B25])                                                                                        

  **n-6/n-3**\                                                                                                              ↑ Overweight risk\
  ↑ at 1--3 months of lactation ([@B21]--[@B23], [@B29]) and from 3 days to 2 months of lactation ([@B24])                  ↑ Inflammation

  **Adrenic acid (22:4 n-6)**\                                                                                              Promotion of CNS development
  ↑ in colostrum ([@B26]) and at 2 weeks of lactation ([@B25])                                                              

  **PAHSA levels**\                                                                                                         ↑ Overweight risk\
  ↓ at 3 days of lactation ([@B28])                                                                                         ↑ Inflammation\
                                                                                                                            ↓ Glucose tolerance

  **Conjugated linoleic acid isomers**\                                                                                     Conflicting results in the 2 available studies ([@B25], [@B26])
  ↑ at 2 weeks of lactation ([@B25])\                                                                                       
  ↓ in colostrum ([@B26])                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*UFA, unsatured fatty acids; SFA, satured fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, unsaturated fatty acids; ALA, α-linolenic acid; EPA, eicosapentaenoic acic; DHA, docosahexaenoic acid; DGLA, dihomo-gamma-linolenicacid; PAHSA, palmitic acid ester of hydroxystearic acid*.

*When available, details on maternal age in the different studies have been reported in the footnotes*.

**Details on maternal age (means±SDs):**

([@B15]): Average age of overweight-obese mothers: 30.5 ± 4.7 years (no statistically significant differences with lean group).

([@B16]): Average age of obese mothers: 30.2 ± 4.7 years (no statistically significant differences with lean group).

([@B17]): Average age of obese mothers: 30.2 ± 5.8 years (no statistically significant differences with lean group).

([@B18]): Average maternal age is reported according to Secretor status, not referring to maternal BMI.

([@B19]): Average age of the mothers in the study: 33.0 ± 4.2 years (considering overweight and lean mothers together).

([@B20]): Average age of overweight mothers: 34.06 ± 3.37 years (no statistically significant differences with lean group).

([@B21]): Average age of overweight mothers: 31.0 ± 5.0 years (no statistically significant differences with lean group).

([@B22]): Maternal age in relation to BMI is not reported.

([@B23]): Average age of overweight-obese mothers: 32.0 ± 4 years (no statistically significant differences with lean group).

([@B24]): Average age of lean mothers: 32.0 ± 4.1 years; Average age of obese mothers: 30.5 ± 5.7 years.

([@B25]): Average age of overweight-obese mothers: 29.9 ± 3.8 years (no statistically significant differences with lean group).

([@B26]): Maternal age in relation to BMI is not reported.

([@B28]): Average age of obese mothers: 35.1 ± 4.3 years (statistically higher than lean group).

*([@B29]): Average age of obese mothers: 30.0 ± 5.7 years (no statistically significant differences with lean group)*.

Nucleotide Derivatives {#s2}
======================

The effects of nucleotides as bioactive substances in the regulation of body functions have been known since long time. *In vitro* and *in vivo* studies showed that nucleotides can promote gut maturation, affect immune modulation enhancing infant antibody response and, in neonatal gut, they can favor the growth of bifidobacteria. In humans, they are considered semi-essential dietary elements, due to the poor capacity of some tissues to synthesize them *de novo*, such as intestinal mucosa and hematopoietic cells. Even if their addition is optional, their pre-constitute mixes are usually present in infant formula milk, to optimize products resembling more accurately mother\'s samples ([@B31]).

*Pyrimidine derivatives*: in the study by Isganaitis et al., the only one, to our knowledge which performs an untargeted metabolomics analysis, liquid chromatography-gas chromatography-mass spectrometry (UHPLC-GC-MS) was applied to BM analysis at 1 and 6 months post-partum; samples collected from women with BMI \> 25 Kg/m^2^ were compared with a control group of lean mothers. Pathway analysis indicated that metabolites related to purine and pyrimidine metabolism were the most represented among those found to be significantly different at 1 month post-partum in BM of overweight-obese mothers compared to normal weight controls ([@B15]).

Among pyrimidine derivatives, orotate was reduced in the milk of obese-overweight mothers by about 25% ([@B15]). Orotate, introduced with food (especially dairy products) or synthesized *de novo* (from glutamine, ATP and CO~2~), is an intermediate metabolite of pyrimidine synthesis and a precursor of uridine-mono phosphate (UMP), a nucleotide that plays a central role in different aspects of human metabolism ([@B32]). BM contains less orotate compared to milk of other species, and mammary gland is assumed to produce it and to have a high rate of UMP synthetase, an enzyme involved in the transformation of orotate into UMP, readily absorbed in gastro-intestinal tract ([@B33]). UMP, in addition to the involvement in nucleic acids synthesis, is the precursor of uridine-di-phosphate (UDP)-sugars, extracellular signaling molecules whose role in inflammatory and immune processes and in obesity-related glucose metabolism has been recently partially clarified.

With regard to the former, UDP-sugars are the major agonist of P2Y14 receptor (P2Y14R), abundantly expressed in leukocytes and other immune/inflammatory cells. They are also involved in the maturation of dendritic cells, in the degranulation of mast cells, and in the promotion of the regenerative processes of hematopoietic cells in the bone marrow ([@B34]). These observations suggest that the reduction of orotate in BM of overweight-obese mothers could have an adverse effect on the neonatal immune processes.

With specific reference to obesity, studies in mice models highlighted the abundant presence of P2Y14R mRNA in the pancreas and its implication in the modulation of insulin secretion. Moreover, the agonist action of UDP-sugars on the P2Y14R would seem to blunt the effect of an high fat diet on weight gain ([@B35]). In agreement with these reports, the reduction of orotate in BM of obese-overweight mothers could have a long-lasting adverse effect on glucose tolerance and on the protection, exerted by these nucleotide derivatives, against weight gain promoted by an inadequate diet.

*Purine derivatives*: among the metabolites belonging to purine pathway, adenosine mono phosphate (AMP) and its catabolite adenine were increased in BM of overweight-obese mothers 1 month after birth, while adenosine monophosphate cyclic (cAMP) was reduced ([@B15]).

Once introduced with the diet, purine nucleotides no longer necessary for cellular functions are degraded by intestinal enzymes to uric acid. In BM, they can derive from the direct passage from blood to milk or from metabolic processes in the mammary gland ([@B31]).

Purines are involved in physiological and pathological processes in all tissues and specifically in adipose tissue. In particular, ATP and adenosine binds to specific receptors of white and brown adipose tissue, both in adipocytes and stromal cells, and their function may be altered in various diseases such as metabolic syndrome ([@B36], [@B37]).

Some of their important functions, exerted mainly through the action of adenosine on A1 receptors, concern the inhibition of lipolysis and the reduction of free fatty acids (whose involvement in the pathogenesis of insulin resistance, diabetes, cardiovascular diseases is recognized), the reduction in insulin resistance is associated with obesity, the increase in leptin production (with an additional beneficial effect on insulin sensitivity), and the increase in the uptake of glucose by adipocytes (with improvement of glucose tolerance but also in triglycerides storage and weigh gain). In agreement, in some studies on obese patients, A1Rs expression was found to be inversely related to the ability to lose weight ([@B38], [@B39]). As well as pyrimidine nucleotides, purine nucleotides positively affect innate immunity and regulates monocytes, macrophages, dendritic cells and mast-cell functions ([@B37], [@B40]). Moreover, their involvement in numerous central nervous system (CNS) functions such as behavior, nociception and locomotion has been highlighted ([@B41]).

Finally, the activation of purine pathway found in BM of overweight-obese mothers ([@B15]) could promote weight gain long after birth, but also improve glucose tolerance and insulin sensitivity in case of obesity, and reduce cardiovascular risk. It may also have a positive effect on the development of immune and anti-inflammatory processes and on neuroprotection.

5-methylthioadenosine {#s3}
=====================

Methylthioadenosine (MTA) was increased 1 month post-partum in BM of obese-overweight mothers and it was also the only metabolite involved in the overlap between BMI and infant total fat content at 1 month ([@B15]). It is a natural nucleoside sulfur containing derived from 5 s-adenosylmethionine (5 SAMe) in polyamine cycle, present in all mammalian tissues including the placenta. 5 SAMe is the substrate of the 5-MTA phosphorylase enzyme, that initiates the salvage pathways leading to the recovery of methionine by one side and adenine (adenosine, AMP) by the other ([@B39]). It is an almost exclusively endogenous metabolite (its presence has been described but not quantified in some edible plants) described for the first time in BM by Isganaitis ([@B15]). Being a purine nucleoside, we can assume a gastro-intestinal absorption, similar to that of the other purines.

5-MTA has important cellular regulatory functions, including gene expression control, inhibition of cell proliferation, activation of lymphocytes, modulation of tumors invasiveness, regulation of apoptosis, and liver-protection ([@B42]). Its potent anti-inflammatory profile has been proven in mice where it prevents lipopolysaccharide-induced death by inhibiting TNFα production (pro-inflammatory cytokine) and iNOS **(**inducible nitric oxide synthase) gene expression, while enhancing the release of IL-10 (anti-inflammatory cytokine) ([@B42]).

In a metabolomics study on an induced rat model of diabetes dating back to 2016, 5 MTA was significantly higher. The study of oxidative stress products showed increased values of superoxide dismutase and hypoxia inducible factor 1 alpha. Both the 5-MAT and the oxidative stress products normalized after treatment with isoflavones, demonstrating their action on the cellular oxidative damage and therefore highlighting related metabolic processes ([@B43]). One year later, an untargeted metabolomics study (UPLC-MS) detected an increase in 5-MTA level in the urines of elderly patients with type 2 diabetes (T2D) ([@B44]). In a further metabolomics study in Mexican adolescents, conducted with to investigate the metabolites associated with a metabolic disease risk z-score (MetRisk z-score), 5-MTA values showed a significant correlation ([@B45]). Finally, 5-MTA levels resulted significantly associated with the BMI in a study conducted on 2,396 unrelated European individuals in the TwinsUK cohort and 724 others of the Health nucleus cohort in three time-points, covering a total interval of 8--18 years ([@B46]).

5-MTA should be considered a protective molecule against chronic inflammation and oxidative stress conditions characterizing obesity and metabolic syndrome. In this respect, MTA increase in BM of overweight-obese mothers ([@B15]) could be protective for long-term overweight, oxidative stress and cardio-metabolic risk.

Sugar-Alcohols {#s4}
==============

Erythritol and ribitol (sugar alcohols) were increased in the milk of obese-overweight mothers 6 months after birth ([@B15]). To the best of our knowledge, only another study investigates sugar alcohols in BM (HPLC), even if erythritol and ribitol were not detectable ([@B47]). While ribitol is an endogenous molecule originating from the reduction of ribose in fibroblasts and erythrocytes, erythritol is a low-caloric sugar-substituted sweetener authorized in the USA and it is also present in different foods. It is absorbed from the proximal intestine by passive diffusion. Recently, its serum increase has been observed, in correlation to weight gain, in a cohort of freshmen. At the same time, through *ex vivo* isotopic techniques, endogenous production of erythritol from glucose ([@B48]) was detected. Given the wide use of low-caloric sweeteners by obese-overweight individuals, further investigation will be useful to clarify whether its increase in the milk of obese-overweight mothers could be related to this or to other metabolic pathways ([@B48]) and the possible long-term effect on glucose metabolism in the infant.

Acylcarnitine and Amino Acids {#s5}
=============================

*Acilcarnitine (ACs) and branched amino acids (BCAAs)*: Three short-chain ACs were increased in the milk of obese-overweight mothers at 6 months after delivery ([@B15]). Short-chain ACs derive from the catabolism of BCAAs, rather than from long-chain fatty acids. Although Isganaitis and colleagues did not detect an increase in BCAAs in the milk of overweight and obese mothers ([@B15]), De Luca et al. ([@B16]), trough UPLC and Tandem Mass (MS/MS), specifically measured free amino acids in the milk of 45 obese women and 45 controls at 1 month post-partum. As result, they found an increase in BCAAs and tyrosine (by 20 and 30%, respectively) in the formers ([@B16]). The increase in serum levels of BCAAs and ACs has been found, in several studies, in obese subjects with or without T2D, and has been more correlated with insulin resistance than with obesity ([@B46], [@B49]--[@B52]). The same group of Isganaitis ([@B45]) carried out an untargeted metabolomic study on 262 children aged 6--10 years divided into two groups (thin and obese non-diabetic): through MS, they found that obese children showed an increase in BCAAs and C3-C5 ACs, significantly correlated with several cardio-metabolic risk indices, including insulin resistance. Interestingly, the pattern was more pronounced in children of mothers with pre-gestational obesity.

An increase in BCAAs may compromise the transport of aromatic amino acids into cells and tissues, reducing the production of serotonin and melatonin (derived from tryptophan) and catecholamines (derived from phenylalanine and tyrosine) in the CNS. Melatonin and serotonin exert their effects both centrally and in the periphery, regulating energy homeostasis through central control of food intake, promoting lipogenesis and glucose metabolism ([@B53]).

Finally, literature data on BCAAs and ACs in obese subjects suggest that exposure to these metabolites is associated with increased metabolic risk later in life. It may also lead to a reduced availability of tryptophan and its serotonin and melatonin derivatives, with neurobehavioral impairment and negative effects on lipid metabolism. The abundance of BCAAs and ACs found in BM ([@B15], [@B16]) could in the same way be linked to an increased metabolic and neuropsychiatric risk in the long distance.

*Glutamine*: glutamine was reduced by about 30% in the milk of obese-overweight mothers at 6 months after delivery ([@B15]). It should be noted that an untargeted metabolomics work on the milk of mothers with gestational diabetes ([@B54]) showed a reduction of glutamine. Its role in promoting better glucose homeostasis as main precursor of gluconeogenesis in the kidney, representing a main substrate for gut-brain gluconeogenesis system, and an inducer of glucagon-like peptide secretion was highlighted in our recent review ([@B11], [@B55]--[@B58]) investigating BM of women with great obstetrical syndromes.

Finally, the reduction of glutamine in the milk of obese-overweight mothers at 6 months after birth ([@B15]) may have long-term adverse effects on glucose homeostasis.

*Asparagine and ornithine*: these aminoacids were reduced by about 50 and 20%, respectively, in the milk of obese-overweight mothers at 6 months after delivery ([@B15]). Several studies on the amino acid profile in obese subjects inversely correlate the amino acid asparagine with the cardio-metabolic risk ([@B46], [@B50], [@B52], [@B59], [@B60]); only one recent study, to our knowledge, correlates also ornithine to T2D ([@B61]).

Their reduction in the milk of obese women could be a long-term metabolic risk factor in infants.

*Aromatic amino acids and derivatives*: tyrosine (in addition to BCAAs) was increased by 30% in the milk of obese women 1 month after birth ([@B16]). An increase in blood tyrosine is frequently reported in obese subjects ([@B45], [@B46], [@B50]--[@B52], [@B62], [@B63]); it is likely to contribute to insulin resistance by glucose production through the pathway of dicarboxilic acid fumarate, the latter also found increased in BM of obese-overweight mothers at 6 months ([@B15]).

High levels of tyrosine in the milk of obese women ([@B16]) could have a negative impact on BMI and cardio-metabolic risk in later ages.

Kynuretic acid was reduced by about 30% in the milk of overweight-obese women 6 month after birth ([@B15]).

In the human body most of kynurenic acid comes from tryptophan catabolism; it is also present in foods and seems to be produced by intestinal microflora in moderate quantities. It can be easily absorbed from the digestive system and transported to the liver and the kidney ([@B64]).

In humans, serum kynurenic acid has been positively associated with several cardio-metabolic risk factors as BMI and insulin-resistance ([@B35], [@B44]): however, some reports in humans disagree with experimental studies where kynurenic acid was able to improve energy metabolism and inflammation in mice fed a high-fat diet and to promote weight loss ([@B65], [@B66]). Thus, it is possible that the elevation of this metabolite in individuals with metabolic risk can represent a compensatory mechanism through which kynurenic acid could perform its beneficial action. In this context, the reduction of kynurenic acid in BM of overweight-obese mothers in the Isganaitis study ([@B15]) could lead to an increased susceptibility to metabolic risk long after birth, rather than being protective.

*2-Aminobutyrate (2-AB):* 2-AB significantly increased in samples collected from overweight-obese womenat 1 month of lactation, increased by about 55% (*p* = 0.03) ([@B15]). 2-AB metabolismis poorly clarified, especially in BM. It seems involved in defense against oxidative stress; reduced glutathione is a central metabolite in the intracellular redox state. Glutathione consumption through oxidative stress activates a compensatory glutathione (GSH) synthetic pathway, accompanied by the synthesis of ophthalmic acid, a GSH analog, from 2-AB ([@B67], [@B68]).

We found a single study investigating 2-Ab in BM; in detail, such metabolite was compared between mothers affected by inflammatory bowel disease (IBD) and healthy mothers at 3 and 6 months of lactation. As result, 2-AB was lower in IBD mothers, potentially related to increased pro-inflammatory activity ([@B69]).

We strongly believe that 2-AB increase in BM from obese mothers could be a compensative mechanism reflecting an increase in oxidative stress.

Polyamines {#s6}
==========

In the study by Ali et al. ([@B17]), 50 mothers (20 lean, 20 obese and 10 obese undergoing dietary treatment), were invited to collect milk at 3 days, 1 month, and 2 months post-partum, to investigate polyamine levels with HPLC. The total polyamine content was reduced in obese mothers at the three time points: the reduction concerned only spermidine and putrescine levels, while spermine was equally represented in the considered groups. The 10 obese mothers undergoing dietary treatment had a higher spermidine and putrescine milk content than the others obese women. The authors assume that the reduced content of polyamines in obese BM could depend on the low quantity of polyamines in the fat- and carbohydrates-rich foods assumed by obese subjects ([@B17]). In agreement, higher levels of polyamines were found in subjects who practice the Mediterranean diet ([@B70]).

Polyamines are widely present in the human body and are involved in many vital functions. Although they mainly derive from endogenous metabolism, a percentage is produced by food and intestinal flora, especially in case of fiber-rich diet. Once introduced with food, they can be absorbed and distributed to different tissues. Their protective role against cardio-metabolic risk has been highlighted by the study of Eisenberg et al., which finds an association between increased consumption of spermidine and decreased cardiovascular events and mortality ([@B71]).

Polyamines also represent oxidative stress and inflammation modulators, often associated with obesity and implicated in the pathogenesis of metabolic syndrome ([@B72]). In a study performed on 60 obese children aged 7--14 years, blood levels of polyamines were significantly higher than in controls, and spermine represented a marker of oxidative stress (NO pathway) and inflammation. The authors believe that the increase in these metabolites could be a protective mechanism against obesity-related oxidative stress ([@B73]). Recently, an association between serum polyamine and T2D levels has been reported in a cohort of patients with metabolic syndrome ([@B74]).

A deregulation of the polyamine system would play a role in neurodegenerative diseases ([@B75], [@B76]) and depression ([@B77]) because of their involvement in the modulation of synapsis and in the regulation of the ionic channels that participate in neuronal excitability ([@B72]).

Finally, the reduction of polyamines in BM could make newborns of obese mothers in the long distance more susceptible to weight gain, oxidative stress, inflammation and cardio-metabolic risk. Moreover, they may be less predisposed to develop neuropsychiatric disorders.

Monosaccharides and Oligosaccharides {#s7}
====================================

Below, we review the few available studies regarding human milk monosaccharides and oligosaccharides (HMOs) variations in BM from overweight and obese mothers instead of normal weight mothers\' samples, and the consequent effects on neonatal metabolism and infant growth.

It should be underlined that ingested HMOs can reach the distal bowel and colon without undergoing any modification or enzymatic hydrolysis in the stomach and upper GI tract. Thus, HMOs can be metabolized by intestinal microbes and 99% of them is eliminated with the stools. The smallest percentage of them (about 1%) can be absorbed through the intestine and reach the circulation, being transferred to several organs, such as brain, liver, respiratory and urinary tract, where they can exert several functions ([@B7]).

1.  \- *1,5Anhydroglucitol (1,5-AG) (monosaccharide)* was found significantly increased in BM from overweight and obese mothers at 1 (*p* = 0.002)and 6 months of lactation (increased by 37% at 6 months, *p* = 0.003) ([@B15]).

1,5-AG is a very interesting metabolite not previously described in BM. Serum 1,5-AG is a validated short-term marker of glycemic control ([@B78]) in patients with type1 and type 2 diabetes, and its role in gestational diabetes is still under evaluation ([@B78]--[@B82]). During pregnancies affected by diabetes, the mean maternal serum values of 1,5-AG were negatively associated with neonatal birth weight and tended to be lower in infants with hypoglycemia; the magnitude of the difference between hypoglycemic and normoglycemic was greater for gestational diabetes ([@B83]).

According to another study, maternal serum level of 1,5-AG at birth was significantly and inversely associated with neonatal complications (such as respiratory distress, hypoglycemia, polycythemia, hyperbilirubinemia, and "large for gestational age" condition), resulting useful in the prediction of complications ([@B84]).

In our opinion, 1,5-AG level in BM could reflect maternal glycemic control and help in predicting neonatal outcome in pregnancies complicated by diabetes, even if it was not identified before in BM and its presence requires further clarification.

1.  \- *Arabinose (monosaccharide)* was found significantly increased in BM from overweight and obese mothers at 6 months of lactation (increased by 72%, *p* = 0.01) ([@B15]).

Arabinose, a five-carbon sugar is a carbon source for many bacteria. In literature, we did not find a metabolic role of such pentose in BM on infant weight gain.

However, in two studies it seems to modulate, in a controversial way, *Pseudomonas aeruginosa* virulence, an opportunistic human pathogen strongly associated with NEC development ([@B85], [@B86]).

Therefore, arabinose could have a potential role on pathogens virulence, improving our knowledge of BM-related effects and contributing to the optimization of formula milks.

1.  \- *Glucose-6-phosphate (monosaccharide)* was significantly higher in BM from overweight and obese mothers at 6 months of lactation (2.07-fold change, *p* = 0.01) ([@B15]).

Glucose-6-phosphate (G6P or α-D-glucose-6-phosphate) is involved in protection against oxidative stress, since it guarantees adequate levels of NADPH to modulate the redox state ([@B87]).

In literature, we found a single very old study measuring such metabolite in human milk during established times of lactation, including G6P, but the results are not clear ([@B88]).

Thus, by the few available evidences, it could be supposed a protective role against oxidative stress and provide energy supply.

1.  \- *Lacto-N-fucopentaose I (LNFPI)* was found significantly reduced in BM from overweight and obese mothersat 1 month of lactation, reduced by about 62% compared to samples of normal weight mothers (*p* = 0.007) ([@B15]).

LNFPI resulted the most relevant influencer of infant growth, significantly associated with lower infant weight at 1 month and with lower weight and less lean and fat mass at 6 months ([@B89]).

LNFPI was also associated with lower infant weight and weight gain at 1 month in another study ([@B18]).

Moreover, LNFPI had positive contributions in height-for-age Z scores at 20 weeks ([@B30]).

LFNP I was lower in BM of mothers of severely stunted infants vs. healthy controls 6 months after delivery ([@B90]).

Therefore, LNFPI in BM seems protective against excessive weight gain in infants and its reduction in overweight and obesity supports the potential pro-adipogenic role of BM in these mothers.

1.  \- *Lacto-N-fucopentaose II and III (LNFPII-III)* were found significantly higher in BM from overweight and obese mothers at 1 month of lactation (*p* \< 0.05) ([@B15]).

At 6 months of lactation, LNFPII was associated with greater fat mass ([@B89]).

BM LNFP III positively contributed to infant height-for-age Z scores at 20 weeks ([@B30]) and it seems to modulate metabolic pathways in mice, improving glucose tolerance, insulin sensitivity and suppressing liver lipogenesis in experimental model of obesity ([@B91]).

In conclusion, little is known on such HMOs and their impact on neonatal growth; LNFP II high level in BM of overweight and obese mothers could suggest a role in infant overweight.

1.  \- *2-Fucosyllactose (2*′*-FL)* was found significantly lower in BM from overweight and obese mothers at 1 month of lactation, reduced by about 38% than normal weight mothers samples ([@B15]).

On the contrary, in another study, 2′-FL would be higher in samples from overweight than non overweight mothers ([@B18]).

Regarding its relation to infant growth, 2′-FL was found lower in BM of severely stunted infants\' mothers vs. healthy controls at 6 months of life ([@B90]).

2′-FL seems directly associated to maternal pre-pregnancy BMI, infant weight up to 1 year of life and also child height up to 5 years of life in offspring of *Se*+ mothers. According to such data, this HMOs seems to affect child growth up to 5 years of life ([@B92]).

Contrarily, in another study 2′-FL did not influence body length, weight, CC or BMI at 4 months of life ([@B93]).

In milk from Se+ mothers, 2′-FL resulted the most abundant HMO, positively associated with infant weight velocity from 0 to 5 months of post-natal age and with fat mass index at 5 months. Thus, 2-FL, currently added to some milk formulas, could be involved in excessive weight gain ([@B94]).

Maternal BMI at 5 months of lactation has been positively correlated with 2′-FL content ([@B94]).

In conclusion, data on 2′-FL seems conflicting; such HMO was associated with a higher maternal BMI and with infant growth, even if its variation in BM from obese mothers should be still defined.

2′-FLwas also hypothesized to increase weight gain when milk formulas are supplemented, effect that results balanced by other HMOs added to such formulations ([@B95], [@B96]).

1.  \- *3-Fucosyllactose (3*′*-FL)* was found significantly increased in BM from overweight and obese mothers at 1 month of lactation (*p* = 0.03) ([@B15]).

Contrarily, in another study, 3′-FL was lower in BM from *Se*+ overweight mothers than normal weigh ones ([@B18]).

Regarding 3′-FL content in BM of overweight and obese mothers, data are controversial and there are not significant associations with infant growth.

1.  \- *Lacto-N-hexaose (LNH)* was found significantly lower in BM of obese mothers at 3--4 months of lactation (*p* \< 0.05) ([@B19]).

At 6 months of lactation, it has been associated with higher infants\' body fat mass ([@B89]); thus, LNH reduction could protect from weight gain.

Moreover, it could contribute to the lower duration of breastfeeding of obese mothers ([@B18], [@B19]).

Lipids {#s8}
======

Lipid composition of BM seems influenced by maternal BMI, influencing its inflammatory and oxidative profile ([@B20]).

Maternal obesity seems related to the increase of n-6/n-3 fatty acid ratio and to the proportion of long-chain fatty acids (LCFAs) in BM. (96, 21--24). LCFAs are less digestible by the neonatal gut; moreover, long-chain polyunsaturated fatty acids (LCPUFAs), such as eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid (AA) are involved in several metabolic pathways, including a role as constituents of cells membranes, and in nervous system and retina development ([@B20]).

Infant growth up to 6 months of life was correlated with higher levels of dihomo-gamma-linolenic (20:3 n6-DGLA), adrenic (22:4 n-6), palmitic acids, conjugated linoleic isomers and reduced level of oleic acids in BM of overweight-obese mothers ([@B25]).

Palmitic acid seems involved in inflammatory and metabolic responses and it could also reduce the oxidation of FAs, alter the insulin response and increase the fat mass ([@B97]).

Adrenic acid is abundant in the brain and in myelin lipids, especially in phosphatidylethanolamine. Its important precursor is AA acid, whose conversion into adrenic acid is particularly active in the early stages of life ([@B26]). Oleic acid was shown to reduce obesity risk and improve the metabolic and lipid profiles in adults ([@B98]). DGLA, other n-6 PUFAs such as AA, and bosseopentaenoic acid (20:5 n-6) are probably involved in the pathogenesis of obesity, promoting adipogenesis and inflammation ([@B20]). This group correlates with a greater increase in the weight for age (WFA) z-score, a smaller increase in the lengh for age z-score and of the CC between 2 weeks and 2 months of age. The effects on long distance obesity are clearly to be determined ([@B25]).

In another study, samples from overweight mothers showed higher levels of saturated FAs (SFAs), lower amount of n-3 FAs and lower ratio of unsaturated (UFA) to saturated (SFA) FAs, and higher n-6/n-3ratio than normal weight samples. Moreover, total SFAs content in BM was positively correlated while MUFA/SFA ratio and UFA/SFA ratio inversely correlated to infant weight and BMI gain up to 13 months ([@B21]).

Successively, the same group investigated the combined effects of maternal pre-pregnancy BMI and food choices on BM triacylglycerols (TAGs) at 3 months of lactation. They evidenced a higher content in 18:3 and a reduced level of 18:0 in normal weight mothers following a recommended food-diet (low fat), than normal weight mothers eating non-recommended foods. Moreover, in samples collected from normal weight mothers eating recommended foods, levels of 50:1 were lower than milk produced by overweight mothers eating recommended food choices. Finally, BM from overweight and obese mothers was characterized by higher levels of saturated FA and lower amount of n-3 FA than non overweight mothers, independently by the diet. Thus, they concluded that maternal BMI and diet can influence the molecular weight distribution of TAGs in BM samples but does not significantly alter their regioisomerism ([@B27]).

In BM from obese mothers, an increase in lipid content (10--20%), and higher levels of ALA, n-6/ n-3 ratio and total PUFA were detect, instead of normal weight mothers. In the same study, total MUFAwere significantly reduced in BM from overweight and obese mothers, while 20:1 n-9 were increased ([@B22]).

In a similar article,n-3 LCPUFA (including EPA and DHA) were lower while n-6 LCPUFA and n-6/n-3 ratio were higher in overweight mothers at 6--7 months of lactation ([@B20]).

A Sweden group demonstrated higher SFAs and n-6/n-3/ratio, and lower n-3LCPUFA (and LA, DHA, EPA) in BM of obese mothers ([@B24]).

Total PAHSA levels \[the fatty acid esters of hydroxy fatty acids (FAHFAs), namely palmitic acid hydroxystearic acids\], endogenous lipid produced by adipocytes in the mammary gland, resulted significantly lower in obese mothers\' samples at 3 days postpartum ([@B28]).

PAHSA seem to promote gut maturation and secretion of GLP-1, which stimulates insulin secretion and increase glucose tolerance ([@B99]).

Interesting findings were also obtained correlating maternal BM lipid content in colostrum and mature milk with infant anthropometry (at 6, 18, and 36 months) and with cognition at 18 months. BM from overweight and obese mothers showed higher SFA levels and n-6/n-3 ratio, and decreased ALA, DHA and MUFA content in mature milk. Infant BMI-z-score at 6 months resulted inversely associated with colostrum levels of n-6 and n-3 LC-PUFAs (e.g., AA and DHA) and positively associated with n-6/n-3 ratio. Cognitive profile evaluated with Bayley scales was positively correlated to colostrum content of n-6 and n-3 PUFAs, DHA, and ALA, and negative correlated to the n-6/n-3 ratio. Thus, according to these data, maternal obesity could increase BMI in the offspring, but n-6/n-3 ratio could impair infant cognition, even if such results should be confirmed ([@B23]).

In a further study BM of obese mothers at 2 months post-partum showed a higher n-6/n-3 FA ratio, while total n-3 PUFAs were reduced of 20%, in association to lower levels of DHA, EPA, docosapentaenoic acid and lutein ([@B29]).

A unique study of Sinanoglu et al. deeply investigated colostrum lipid content according to maternal BMI. As result, docosadienoic acid (C22:2 n-6), conjugated LA isomers C18:2*c*9*t*11 (rumenic acid) and C18:2*t*11*t*13 were higher in normal weight mothers\' BM; total n-3,decanoic (C10:1), tridecanoic (C13:0) and adrenic (C22:4n-6) acids were higher in obese mothers; ALA (C18:3n-3) was higher in overweight mothers\' samples ([@B26]).

Interest in conjugated LA isomers has grown in recent years due to the increasing number of experimental studies attributing them anti-inflammatory, anti-carcinogenic, antiadipogenic, antidiabetic, and anti-hypertensive properties in animal models. Their increase is probably causedby the excessive dietary intake ([@B25]). They may represent afuture nutritional tool to prevent diseases as metabolic syndrome but studies on humans are still necessary ([@B100]--[@B102]).

The n-6/n-3 ratio in BM increases in proportion with the fat in the diet: this could lead to a higher adipose tissue accumulation in neonates fed with obese mothers\' BM. The authors speculate that the increase of PUFA in overweight and obese mothers\' BM could determine cardio-protective (probably) compensatory mechanism for their infants, since such mediators are related to a better metabolic profile ([@B26]).

Conclusions {#s9}
===========

Maternal obesity seems a major risk factor for excessive fetal growth ([@B103]), infant overweight and children obesity ([@B104], [@B105]). The negative impact of obesity on children\'s health can lead to the early development of T2D, the premature onset of cardiovascular complications and, in general, a higher risk of early mortality ([@B106]). Recent literature has shown increasing interest in the impact of such disease on the nervous system and in particular, in the field of neuropsychiatric and behavioral disorders (mainly attention-deficit/hyperactivity disorder, conduct disorders and autism), described only sporadically in the past but now confirmed by large population studies ([@B107], [@B108]). Besides, a reduction in prefrontal cortex thickness and associated executive function deficit was described in a large cohort of obese children aged 9--10 years ([@B109]).

In the present review of metabolomics studies on BM from overweight-obese mothers highlighting the differences with samples from the lean ones, some of the metabolites that differentiate the two groups---aminoacids, acyl-carnitines, lipids and oligosaccharides---have been found altered in subjects with the same characteristics and in experimental modes of obesity in several studies and in a relevant number of cases. For these metabolites, which can be considered "major," the results obtained from the aforementioned studies allow for more reliable hypotheses on the meaning of their alteration in BM long after birth. However, it should be noted that it is difficult to make qualitative assessments of the relevance of one group of metabolites in relation to the other.

Between these "major" metabolites, all aminoacids found altered could promote cardio-metabolic risk unlike their derivatives ("minor" metabolites) whose reduction (kinurenic acid) or increase (2-aminobutyrate) might give protection against cardio-metabolic risk from oxidative stress and inflammation.

Among HMOs, those decreased (LNFPI, 2FL, LNH) seem to have a protective effect against excessive weight gain, while NFPII increase could predispose to it.

Our analysis of the papers investigating fatty acids in BM of overweight-obese mothers, in agreement with the unique available meta-analysis ([@B110]), highlights an increase in saturated fatty acids, a reduction in monounsaturated fatty acids, a reduction in n-3 LCPUFA, and an increase in n-6/n-3 ratio in most of them. The first two effects could promote excessive long-term weight gain and associated inflammation, as well as reduce glucose tolerance. The increase in the n-6/n-3 ratio, due to the reduction in n-3 or increase in n-6 may impair, as previously mentioned, sensorineural development and promote adipogenesis and inflammation.

Between the "minor" metabolites, the alteration of nucleotides derivatives could promote weight gain after birth and have, except for adenine and MTA, a negative impact on the risk of insulin resistance, T2D, cardio-metabolic disease and on the onset of neurological problems. Increase of adenine, while promoting weight gain, could hinder the insulin resistance associated with obesity (and cardio-vascular risk) and have a positive impact on immune and neurological development. Even MTA increase could be protective against cardio-metabolic risk in offspring.

Lastly, reduction of polyamines could correlate with outcomes related to obesity in the long distance.

Finally, metabolites variations in BM samples collected from overweight-obese mothers and the potentially correlated effects pointed out above, still need further investigations and should be confirmed in future studies on larger sample: metabolomics seems the most suitable technology in this regard. It can lead to the comprehensive description of such biofluid and the related effects on breastfed subjects, potentially highlighting personalized needs of BM supplementation or short and long-term prevention strategies to optimize offspring health.

In our opinion, such topic is of major importance, since pediatric health starts in intrauterine and perinatal life.
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